A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.
A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using Parameters Obtained by Computed Tomographic Pulmonary Angiography.
Sponsor: Shengjing Hospital
Listed as NCT05098769, this observational or N/A phase trial focuses on Deterioration, Clinical and Pulmonary Embolism and Thrombosis and remains actively recruiting participants. Sponsored by Shengjing Hospital, it has been updated 8 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Mar 2026 — Present [monthly]
Recruiting
-
Oct 2025 — Mar 2026 [monthly]
Recruiting
-
May 2025 — Oct 2025 [monthly]
Recruiting
-
Sep 2024 — May 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Nov 2023 — Jul 2024 [monthly]
Recruiting
-
Dec 2021 — Nov 2023 [monthly]
Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Recruiting
First recorded
Jan 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shengjing Hospital
For direct contact, visit the study record on ClinicalTrials.gov .